improvement in visual acuity six months post-operatively. Histological examination of explanted corneal tissue confirmed the presence of neurofilament+ axon profiles in the cornea after neurotisation. Analysis of MEG data identified a clear absence of evoked response in the anaesthetic (right) cornea prior to neurotisation. Following neurotisation, an evoked response was detected in same (right) cornea, which was localized to the ipsilateral motor cortex, suggesting that the origin of the (right) corneal sensation after neurotisation was derived from the contralateral (left) forehead.
PURPOSE:
Traumatic peripheral nerve injuries often result in the permanent loss of muscle function. One reason for the failure of recovery is the end-stage process of muscle fibrosis whereby an increase in extracellular matrix (ECM) interferes with the functional properties of muscles. It has been widely observed that denervation results in the abnormal accumulation of ECM. However, little is known about the cellular and molecular mechanisms of this fibrosis in denervated skeletal muscles in comparison to other tissues. One particular cellular signaling cascade of interest is the transforming growth factor beta 1 (TGFβ-1) as TGFβ-1 and its downstream effectors are widely accepted as being critically important to the development of fibrosis. In addition to TGFβ-1's role in the fibrotic process, it is also known to play a critical role in synaptogenesis. As neuromuscular junction (NMJ) degradation and fibrosis both occur following denervation, we sought to establish if there is a temporal correlation between these two phenomena. With TGFβ-1's ubiquitous involvement in both synaptogenesis and fibrosis, it is our hypothesis that NMJ degradation initiates the phenotypic change of skeletal muscle tissue to fibrotic tissue via a TGFβ-1 dependent mechanism.
METHODS:
A denervation model was created in 6 week old C57BL/6 mice by excising 10 mm segments from the right sciatic nerve and suturing the proximal nerve to the gluteal muscle with 9-0 suture so as to prevent regeneration. Denervated gastrocnemius muscles were then harvested at multiple time points for analysis by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot for levels of TGFβ-1 and possible downstream targets. Passive muscle stiffness measurements were also performed by subjecting isolated denervated muscles to ramp stretches and then measuring resistance to stretch. Muscle collagen content was measured using a hydroxyproline assay and visualized with Masson's trichrome staining.
RESULTS:
qRT-PCR was used to confirm the transcriptional changes associated with the switch towards a fibrotic phenotype. One week after injury, expression of TGFβ-1 in denervated gastrocnemius muscles was significantly increased compared to muscle from the contralateral side. Connective tissue remodeling proteins including matrix metalloproteinases (mmp-3) and scleraxis (scx) were also significantly upregulated. Genes involved in inflammation (TNFα) and collagen deposition (Col1A1 and Col1A2) were not significantly changed at this time point. Gene expression levels in muscle samples one month after denervation showed a similar trend.
CONCLUSIONS:
Our preliminary data suggests that TGFβ-1 signaling plays a key role in the early stages of the phenotypic switch towards muscle fibrosis after nerve injury. There is a temporal correlation between NMJ degradation and upregulation of the pro-fibrotic genes postdenervation. This is an important first step in establishing this correlation prior to determining causality and supports further investigation in this critically important area.
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Growth Hormone Enhanced Recovery After Chronic Denervation Injury: Augmenting Axonal Regeneration, Promoting Motor Reinnervation, and Improving Muscle Function INTRODUCTION: Several experimental studies suggest that growth hormone-based therapies have the potential to accelerate and augment axonal regeneration while simultaneously act directly on muscle and Schwann cells (SCs) to minimize denervation atrophy prior to re-innervation. The purpose of this study was to assess the impact of growth hormone (GH) therapy on preventing the deleterious effects of chronic denervation (CD) injury on nerve regeneration and resulting muscle function. We hypothesized that systemic GH therapy can maintain chronically-denervated muscle and SCs, accelerate axonal regeneration, and improve murine extremity function in the setting of chronic denervation (CD) by preserving muscle mass and promoting motor reinnervation.
METHODS:
We utilized a newly-developed, rat forelimb CD model to assess the effects of GH therapy on: a) improving nerve regeneration; and b) preventing muscle atrophy and augmenting muscle re-innervation and function. Four groups of rats were examined: (1) Group-1 (n = 8) underwent 8 weeks of median nerve CD injury followed by repair; (2) Group-2 (experimental, n = 8) underwent 8 weeks of median nerve CD followed by repair and treatment with highly purified lyophilized pituitary porcine GH (0.6 mg/ day); (3) Group-3 animals (n = 8) underwent no median nerve CD injury; (4) Group-4 animals (n = 8) were naïve controls. All animals underwent weekly muscle functional testing followed by median nerve and flexor muscle harvest for nerve histomorphometry, muscle weight, atrophy, and re-innervation analysis. To enable the assessment of the effects of GH therapy on maintaining denervated muscle and SCs: Group-1 animals also underwent 8 weeks of contralateral sciatic nerve CD; Group-2 animals underwent 8 weeks of sciatic nerve CD (w/ GH treatment as stated above); Group-3 animals underwent 1 week of sciatic nerve CD; and Group-4 animals underwent no sciatic nerve CD. The sciatic nerve and lateral gastrocnemius muscle were harvested after completion of sciatic nerve CD injury time point to assess for SC proliferation/senescence markers (via qPCR) and muscle atrophy (via muscle weight and crosssectional area muscle staining).
RESULTS:
Median nerve regeneration was higher in GH-treated animals when compared to untreated controls as measured by axon density (p < 0.005), axon diameter (p < 0.0001), and myelin thickness (p < 0.0001). Furthermore, GH improved muscle re-innervation (27.9% vs 38.0% NMJs re-innervated; p < 0.02) and prevented muscle atrophy (865 ± 48.3 vs 1081 ± 101.4 μM 2 ; p < 0.02). GH-treated rats demonstrated greater functional muscle recovery as compared to untreated controls (hand grip: 1.8 ± 0.3 N vs. 1.0 ± 0.1 N, p=0.001). Lastly, Group 2 animals demonstrated higher expression of SC proliferation and migration markers, c-Jun & erbB-3, and less muscle atrophy (0.21 ± 0.02 g vs. 0.17 ± 0.01 g; P=0.55) when compared to Group 1 at 8 weeks after sciatic nerve CD.
CONCLUSION:
Systemic GH therapy can improve nerve regeneration and maintain chronically-denervated muscle by promoting re-innervation and subsequent muscle function.
